CBER targets four stem cell firms with untitled letters
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyComplianceNorth AmericaQuality Assurance and ControlRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyComplianceNorth AmericaQuality Assurance and ControlRegulatory Intelligence/Policy